GDC-6036 + erlotinib

GDC-6036 + erlotinib is an **investigational combination therapy** consisting of GDC-6036, a small molecule, covalent, irreversible inhibitor of KRAS G12C, and erlotinib, a small molecule, reversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR). GDC-6036 is designed to selectively and irreversibly bind to the KRAS G12C mutant protein, locking it in an inactive state and blocking its oncogenic signaling. Erlotinib inhibits cell proliferation by targeting the EGFR, which is overactive in various cancers. The combination is currently being studied for its safety and preliminary efficacy in patients with KRAS G12C-mutant advanced or metastatic solid tumors, primarily non-small cell lung cancer (NSCLC)[1][2][3][4][5][6][7].

Brand names

Tarceva